233 388

Cited 26 times in

Real-World Treatment Patterns and Clinical Outcomes in Patients With Stage III NSCLC: Results of KINDLE, a Multicountry Observational Study

Authors
 Abdul Rahman Jazieh  ;  Huseyin Cem Onal  ;  Daniel Shao Weng Tan  ;  Ross A Soo  ;  Kumar Prabhash  ;  Amit Kumar  ;  Reto Huggenberger  ;  Stephen Robb  ;  Byoung-Chul Cho 
Citation
 JOURNAL OF THORACIC ONCOLOGY, Vol.16(10) : 1733-1744, 2021-10 
Journal Title
JOURNAL OF THORACIC ONCOLOGY
ISSN
 1556-0864 
Issue Date
2021-10
MeSH
Carcinoma, Non-Small-Cell Lung* / pathology ; Chemoradiotherapy ; Humans ; Lung Neoplasms* / pathology ; Male ; Middle Aged ; Neoplasm Staging ; Retrospective Studies
Keywords
Combined modality ; Concurrent chemoradiotherapy ; Immunotherapy ; Lung cancer ; Stage III NSCLC
Abstract
Introduction: Stage III NSCLC is a heterogeneous disease requiring a multimodal management approach. We conducted a real-world, global study to characterize patients, treatment patterns, and their associated clinical outcomes for stage III NSCLC.

Methods: KINDLE was a retrospective study in patients with stage III NSCLC (American Joint Committee on Cancer, seventh edition) diagnosed between January 2013 and December 2017, with at least 9 months of documented follow-up since index diagnosis. In addition to descriptive statistics, Kaplan-Meier methodology evaluated survival estimates; two-sided 95% confidence interval was computed. Cox proportional hazards model was used for univariate and multivariate analyses.

Results: A total of 3151 patients from more than 100 centers across 19 countries from Asia, Middle East, Africa, and Latin America were enrolled. Median age was 63.0 years (range: 21.0-92.0); 76.5% were males, 69.2% had a smoking history, 53.7% had adenocarcinoma, and 21.4% underwent curative resection. Of greater than 25 treatment regimens, concurrent chemoradiotherapy was the most common (29.4%). The overall median progression-free survival (95% confidence interval) and median overall survival (mOS) were 12.5 months (12.06-13.14) and 34.9 months (32.00-38.01), respectively. Significant associations (p < 0.05) were observed for median progression-free survival and mOS with respect to sex, region, smoking status, stage, histology, and Eastern Cooperative Oncology Group status. In univariate and multivariate analyses, younger age, stage IIIA, better Eastern Cooperative Oncology Group status, concurrent chemoradiotherapy, and surgery as initial therapy predicted better mOS.

Conclusions: KINDLE reveals the diversity in treatment practices and outcomes in stage III NSCLC in a real-world setting in the preimmuno-oncology era. There is a high unmet medical need, necessitating novel approaches to optimize outcomes.
Files in This Item:
T202125018.pdf Download
DOI
10.1016/j.jtho.2021.05.003
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Cho, Byoung Chul(조병철) ORCID logo https://orcid.org/0000-0002-5562-270X
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/187653
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse

Links